Our purpose was to assess noninvasive imaging in detection of subclinical atherosclerosis and to examine novel invasive modalities to describe prevalence and temporal changes in putative characteristics of "high-risk" plaques. BACKGROUND Conventional coronary imaging cannot identify "high-risk" lesions.
Atherosclerosis is a systemic disease in which the clinical sequelae only weakly correlate with its extent or severity. Furthermore, sudden death or acute coronary syndromes are frequently the first manifestation of previously subclinical atherosclerosis, and the majority of such events (i.e., 60% to 70%) occur as a result of plaque rupture at sites with noncritical luminal narrowing (1) (2) (3) (4) (5) . Pathologic studies have correlated specific coronary plaque characteristics with fatal ischemic events, but conventional imaging techniques, such as quantitative angiography and quantitative intravascular ultrasound (IVUS), cannot reliably identify high-risk, ruptureprone, plaques prospectively (6) . Thus, development of novel coronary imaging modalities to detect structural and compositional plaque characteristics has been the subject of intensive preclinical and clinical research (7, 8) . In parallel with the advances in novel invasive imaging, noninvasive multislice computed tomographic angiography (MSCTA) has matured to the extent that it can reliably identify flow-limiting coronary lesions in relatively unselected patients.
The aim of this study was four-fold: 1) to determine the potential of MSCTA in the detection of subclinical, non-flow limiting coronary atherosclerosis; 2) to assess the prevalence of high-risk characteristics in such plaques with two novel IVUS-based imaging modalities (palpography and echogenicity plaque characterization); 3) to assess temporal changes in IVUS-based plaque characteristics of high-risk lesions; and 4) we attempted to relate changes in imaging parameters to changes in systemic biomarker levels.
METHODS
Study design and patient selection. This was a prospective, observational, single-center pilot study. The study design has been described in detail elsewhere (9) . Briefly, patients with stable angina, unstable angina, non-STsegment elevation, or ST-segment elevation myocardial infarction (STEMI), referred for percutaneous coronary intervention (PCI), were eligible for inclusion. Major clinical exclusion criteria included significant renal dysfunction (creatinine Ͼ2 mg/dl), prior coronary intervention in the region of interest (ROI), life expectancy Ͻ1 year, or factors that made follow-up difficult. Major imaging-related exclusion criteria included coronary anatomy that precluded safe IVUS examination of a suitable ROI or criteria that precluded acquisition of diagnostic noninvasive angiographic images (irregular heart rhythm or inability to hold breath for 20 s). Between March 2003 and November 2003, 90 consecutive patients were enrolled, and follow-up was completed in summer 2004. The study vessel was preferably a non-intervened artery. At the discretion of the operator, a second artery could be studied. The ROI was defined on the basis of MSCTA, using landmarks, such as branches or the vessel origin. At six months follow-up, patients underwent repeat invasive imaging. The medical ethics committee of the Erasmus Medical Center Rotterdam approved the study protocol, and all patients provided written informed consent. Quantitative coronary angiography and IVUS. Quantitative angiographic analyses were performed by a core laboratory (Cardialysis, Rotterdam, the Netherlands) with the use of edge-detection techniques (CAAS II, Pie Medical, Maastricht, the Netherlands). Mean and minimum luminal diameters and diameter stenosis were measured in at least two, preferentially orthogonal, projections and averaged.
The IVUS was performed with commercially available catheters (30 MHz, Ultracross, or 40 MHz, Atlantis SR Pro, Boston Scientific, Santa Clara, California) using standard procedures with an automated pullback device (0.5 mm/s) (10) . Data were stored on videotape, transformed into the Digital Imaging and Communication in Medicine (DICOM) image standard, and archived. Quantitative analysis was performed by the core laboratory with validated software (Curad, version 3.1, Wijk bij Duurstede, the Netherlands) and retrospective image-based gating (11) . The borders of the external elastic membrane (EEM) and of the lumen were traced. The enclosed area was defined as the coronary plaque plus media area (subsequently referred to as plaque area). Significant plaque was defined as a plaque that occupied 50% or more of the cross-sectional vessel area circumscribed by the EEM. Other IVUS measurements included length of the ROI, lumen volume, and vessel volume. Plaque volume (PV) was calculated as vessel volume minus lumen volume. The interobserver variability was determined by re-analyzing the baseline and follow-up IVUS recordings of 16 patients by a different core lab analyst. Sixteen patients (32 recordings) were randomly selected among recordings that fulfilled the following two criteria: 1) ROI Ͼ30 mm long, and 2) both pullbacks were performed with the same type of IVUS catheter (30 MHz catheter). Novel IVUS-based plaque imaging: echogenicity. We used a computer-aided, gray-scale value analysis program for plaque characterization (12) . On the basis of the mean gray level (brightness) of the adventitia, plaque was classified as brighter (hyperechogenic) or less bright (hypoechogenic) than the adventitia. Calcified plaque was defined as plaque brighter than the adventitia with associated acoustic shadowing. The variables measured in the previously defined ROI included hypoechogenic PV and hyperechogenic PV (mm 3 ) and relative plaque echogenicity, calculated as (hypoechogenic PV/sum of hypoechogenic and hyperechogenic PV) ϫ 100. For the comparison with MSCT, plaque within the ROI was considered calcified if it contained calcium in at least two consecutive cross-sections corresponding to an IVUS segment with a length of at least 0.5 mm. Novel IVUS-based plaque imaging: palpography. Palpography is an IVUS-based technique that assesses the local mechanical properties of the coronary plaque. The technique measures the relative displacements of backscattered radiofrequency signals, recorded during IVUS acquisition, at two different blood pressure levels to detect differences in deformability or strain of various plaque components. As such, lipid-rich plaques will deform more and thus show a higher strain value compared with calcified or fibrous plaques (13 dova, California). With previously described and validated methodology, plaque strain values were assigned a ROtterdam Classification (ROC) score ranging from 1 to 4 (ROC 1: 0% to 0.6%; ROC 2: 0.6% to Ͻ0.9%; ROC 3: 0.9% to Ͻ1.2%; ROC 4: Ͼ1.2%) (13-16). The parameters measured included the number of ROC 3 or 4 spots in the ROI and the density of ROC 3/4 spots, defined as the total number of ROC 3 and 4 scores that were counted in all cross sections that were acquired at 1-mm intervals in the whole ROI. This number was divided by the length of the ROI and multiplied by 10 to normalize to the pullback length. MSCTA. All scans were performed on a 16-row detector scanner (Sensation 16, Straton, Siemens, Forchheim, Germany). The scan protocol and image reconstruction parameters were recently published (17) . The dataset with least motion artifacts was loaded on an off-line workstation (Leonardo, Siemens) and the ROI identified on multiplanar reconstructions, on the basis of anatomic landmarks. Datasets were loaded on a semi-automated vessel-tracking software program and a central lumen line created throughout the ROI. Ten through 30 cross sections were reconstructed orthogonal to the center of the lumen and analyzed independently by two observers. Disagreements were resolved by consensus. Plaque was defined as an abnormal mass within the artery wall, clearly distinguishable from epicardial fat and the coronary lumen. On the basis of manually measured maximal thickness, plaques were classified as small (Ͻ1 mm), medium (1 to 2 mm), or large (Ͼ2 mm). Calcification was defined by the presence of high-density components (Ͼ130 Hounsfield units).
Lipoprotein levels and biomarkers. Plasma concentrations of total cholesterol, high-density lipoprotein cholesterol (HDL-C), and triglycerides were measured in the local laboratory. The Friedewald formula was used to derive low-density lipoprotein cholesterol (LDL-C) levels (18) . Blood samples for additional biomarker analysis were stored at Ϫ70°C. Serum C-reactive protein (Diagnostic Systems Laboratories, Webster, Texas), plasma interleukin 6, and tumor necrosis factor-alpha (R & D Systems, Minneapolis, Minnesota) were measured in the Human Biomarker Center (GlaxoSmithKline, Philadelphia, Pennsylvania) on the basis of protocols provided by the manufacturer. Lipoprotein associated phospholipase A 2 activity assay was measured by the proportional release of aqueous 3 H acetate resulting from the enzymatic cleavage of the 3 H acetylplatelet activating factor substrate (100 mol/l). N-terminal 
RESULTS

Patient population.
A flow diagram detailing the number of patients undergoing multimodality coronary imaging is presented in Figure 1 . Sixty-seven patients underwent serial invasive imaging of non-culprit segments of coronary artery at baseline and 196 Ϯ 19 days later. Nine patients had one or both IVUS recordings that were not analyzable, owing to artifact or use of an incorrect scale. An additional three patients could not be analyzed for IVUS echogenicity, owing to extensive calcification overshadowing a large part of the adventitia, which is used as a reference for the interpretation of gray-scale values of surrounding tissue. Reasons for inaccurate palpogram readings (n ϭ 18) were related to extensive catheter motion during data acquisition. Baseline characteristics of patients who completed the study are shown in Table 1 . They were comparable to those of the entire cohort of 84 patients enrolled at baseline (not shown). Almost all patients (99%) received treatment with a statin within the six-month study period, mainly as a result of starting treatment in the group who presented initially with Mean total cholesterol, LDL-C, HDL-C, and triglyceride values for patients who completed the study are presented in Table 2 .
MSCTA versus IVUS at baseline. The MSCTA and IVUS were compared, at baseline, in 61 patients (67 vessels). The sensitivity and specificity of MSCTA to detect significant plaque identified on IVUS (Ͼ50% EEM area obstruction or the presence of calcification on two consecutive slices) was calculated for the entire ROI and for 5-mm sub-segments (Table 3 ). The sensitivity, specificity, and positive and negative predictive values of MSCTA for detection of any significant plaque was 86%, 69%, 90%, and 61%, respectively. The sensitivity of MSCTA to detect plaque was 60% (30 of 50) for small (Ͻ1 mm), 76% (80 of 105) for medium (1 to 2 mm), and 79% (26 of 33) for large (Ͼ2 mm) plaques.
Reproducibility of IVUS measurements.
Interobserver variability for IVUS analysis (n ϭ 32 pullbacks) showed no systematic error and good reproducibility. Mean differences in area (mm 2 ) measurements were: 0.04 Ϯ 0.56 for EEM, 0.02 Ϯ 0.50 for lumen, and Ϫ0.06 Ϯ 0.59 for plaque. The mean difference in PV (mm 3 ) was Ϫ2.43 Ϯ 22. Conventional imaging: quantitative coronary angiography and IVUS. There were no statistically significant changes in the angiographic variables measured in the ROI (Table 4) . Likewise, IVUS-derived measurements remained unchanged in matched segments (Table 5 ). Figure 2 illustrates the spread of the individual data points for PV. When patients were grouped according to initial diagnosis (i.e., STEMI, unstable angina, stable angina), there were no significant changes in either angiographic or IVUS measurements between baseline and follow-up (data not shown). Novel IVUS-based imaging. Temporal changes in plaque characteristics on the basis of IVUS-based palpography and echogenicity are shown in Tables 5 and 6 . At baseline, the predominant plaque component was hypoechogenic tissue (91.6% of PV). There was no significant change in the absolute volume of hypoechogenic or hyperechogenic plaque over the course of the study. On palpography, both the absolute number of high-strain spots (grade 3/4) in the ROI (p ϭ 0.009) and their density per cm (p ϭ 0.012) decreased significantly between baseline and follow-up. This decrease in the overall population was largely driven by changes in the subgroup of patients with STEMI; this group had both the highest number of high-strain spots at baseline and the most marked relative decrease during follow-up, compared with patients with other clinical presentations. At 6-month follow-up, the density of highstrain spots (1.2 Ϯ 1.4/cm) was comparable among clinical subgroups. Representative imaging findings are presented in Figure 3 . Correlation of biomarkers with imaging techniques. Not surprisingly, several inflammatory mediators (C-reactive protein, interleukin-6, lipoprotein-associated phospholipase A 2 ) and a marker of hemodynamic stress (NT-proBNP) decreased over time, particularly in patients presenting with acute coronary syndromes. There were no significant correlations noted between circulating biomarkers and imaging parameters (data not shown). Among lipid parameters (total cholesterol, LDL-C, HDL-C, and triglycerides), a correlation with the change in IVUS-derived plaque area was only noted for the change in HDL-C (Pearson correlation coefficient Ϫ0.37, p Ͻ 0.05, data not shown). Adverse events. One patient died two weeks after inclusion, because of a second MI. All imaging procedures were performed without complications.
DISCUSSION
The major findings of the study were four-fold. First, with IVUS as a gold standard, noninvasive MCSTA can identify atherosclerotic plaque, in vessels with only minimal angio- graphic disease, with high sensitivity and moderate specificity. Second, further investigation of such plaque with novel IVUS-based imaging techniques (palpography and echogenicity) showed that features potentially indicative of vulnerable plaques are both widespread and highly prevalent. Third, although conventional imaging with quantitative coronary angiography and IVUS demonstrates no significant changes in lumen or plaque dimensions, the biomechanical properties of the plaques, assessed by palpography, showed significant changes over a relatively short period. Finally, circulating levels of measured biomarkers showed no significant correlations with focal imaging end points identified by conventional and novel imaging modalities. Subclinical atherosclerosis: role of noninvasive imaging. The development of noninvasive angiography with MSCTA can be used to reliably identify significant epicardial coronary atherosclerosis (20) . Recent studies have shown its potential for detecting non-obstructive coronary plaques in highly selected patients (21, 22) . Our results extend these findings by showing that non-obstructive coronary plaque can be detected, in an arbitrarily selected ROI, with moderately high sensitivity and specificity in a broader patient population; however, when examined in more detail, with novel invasive techniques, we found that putative "high-risk" characteristics (i.e., hypoechogenic plaques with a high-strain pattern) were very common. This observation provides additional arguments to support recommendations discouraging the indiscriminate use of noninvasive coronary imaging to detect subclinical atherosclerosis at the present time (23) . Subclinical atherosclerosis: insights from novel invasive techniques. We have previously validated the potential of palpography to identify thin-capped fibroatheromas in vitro (13, 14, 24, 25) . Subsequently, we showed that the number of high-strain spots in culprit epicardial vessels was correlated with clinical presentation (16) . The present study extends these findings by demonstrating that, within arbitrarily selected segments of non-culprit vessels, high-strain areas were quite common, despite only mild angiographic disease. The most marked changes occurred in patients with an acute MI, most of who were statin-naïve (93%) at the time of the initial presentation. Although acute MI patients had a higher extent of high strain spots, all subgroups were comparable six months later, regardless of the initial presentation. Interestingly, the persistence of abnormal strain patterns might reflect the inadequacy of standard medical care. This hypothesis would be consistent with recent data that indicate the need for intensive intervention for LDL-C (Ͻ70 mg/dl) and inflammation (C-reactive protein Ͻ2 mg/l) to achieve the best clinical outcomes in the course of therapy with statins in post-ACS patients (26, 27) .
Prior studies suggest that gray-scale echogenicity is related to the histological components of carotid and coronary plaques (28 -30) . Although carotid plaque echogenicity can be assessed noninvasively, assessment of coronary plaque echogenicity requires invasive techniques and has been restricted to research settings. In the present study, we used a quantitative computer-assisted index of echogenicity, on the basis of gray-scale values of adventitia, and demonstrated that hypoechogenic tissue was the predominant plaque component. We found no significant change in absolute hypoechogenic or hyperechogenic PV over the average six months. Our findings differ from the observations of Schartl et al. (31) , who found a small but significant increase in the hyperechogenic plaque component; however, their study had a longer follow-up period and patients had intensive, carefully monitored, statin therapy. A recent study conducted at our institution suggested that the changes in plaque echogenicity require a much longer period to occur (more than two years) (32) . Accordingly, the high preponderance of hypoechogenic plaque (Ͼ90% of the PV) cou- The IBIS Study (33, 35) . Third, although our results underscore the heterogeneity of coronary atheroma, much larger studies are needed to ultimately define the role of novel plaque imaging techniques in clinical practice. Fourth, our attempt to relate circulating biomarkers to coronary plaque imaging in an arbitrarily selected ROI can only be regarded as exploratory. We did not further discuss this possible interaction because the correlations we found were weak. Fifth, the suboptimal spatial and temporal resolution of the 16-slice MSCT scanner precludes accurate assessment of coronary artery segments Ͻ2 mm. Although the ROI as selected by MSCT was chosen randomly, distal coronary segments are inevitably underrepresented. The same argument holds true, however, for IVUS examination of the coronary tree, where for safety reasons only the larger coronary segments are targeted for interrogation. Conclusions. Mild angiographic disease is associated with large atherosclerotic plaques identified with noninvasive MSCTA. This study also confirms that conventional invasive imaging modalities frequently reveal static luminal and plaque dimensions, whereas novel IVUS-based plaque palpography can detect significant alterations in coronary plaque characteristics over a relatively short time interval. Our results highlight the dynamic changes in the strain of coronary plaques that are remote from the culprit lesions, particularly in patients with MI. Whether the persistence of a high-strain pattern is a harbinger of cardiovascular events remains to be determined in much larger future studies. The novel imaging modalities used in this study provide insights into plaque biology, whereas temporal changes detected with these modalities might eventually serve as intermediate end points in interventional trials.
